Intensity Tx (INTS) Short-Term Debt to Capital

Intensity Therapeutics (INTS) is a leading developer of the DATH system for targeted tumor combat, investing in the creation of non-toxic therapy methods. This chart illustrating the price evolution of the stock shows that the indicator is 0.00. Stringent FDA requirements and the complexity of biotechnology create barriers for new entrants. Furthermore, patent protection of chemical formulas and costly clinical validation provide the company with a sustainable competitive advantage.

The macro-resilience of Intensity Therapeutics (INTS) is driven by the independence of biotechnological developments from economic cycles and GDP. This metric compares liabilities with a maturity of up to one year against equity, identifying default risks or developmental stagnation. By analyzing the trend of short-term loans as a share of equity, an investor can promptly detect signs of debt overheating that threaten the company's financial stability.